Heplisav B ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

heplisav b

dynavax gmbh - lifrarbólga b yfirborðs mótefnavaka - lifrarbólga b - bóluefni - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Aspaveli ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

aspaveli

swedish orphan biovitrum ab (publ) - pegcetacoplan - blóðrauði, ofsakláði - Ónæmisbælandi lyf - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Hydroxyurea medac Hart hylki 500 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

hydroxyurea medac hart hylki 500 mg

medac gesellschaft für klinische spezialpräparate gmbh - hydroxycarbamidum inn - hart hylki - 500 mg